Andreas Argyrides
Stock Analyst at Chardan Capital
(4.32)
# 1,336
Out of 5,051 analysts
378
Total ratings
45.2%
Success rate
9.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiated: Hold | $1.5 | $1.85 | -18.70% | 1 | Oct 13, 2026 | |
| AGEN Agenus | Initiated: Buy | $40 | $8.19 | +388.40% | 1 | Sep 21, 2026 | |
| IRD Opus Genetics | Rated: Buy | $13 → $16 | $5.18 | +208.88% | 3 | Sep 9, 2026 | |
| EYPT EyePoint | Downgraded: Hold | $65 → $5 | $3.85 | +29.87% | 2 | Aug 18, 2026 | |
| RANI Rani Therapeutics Holdings | Initiated Coverage: Buy | $6 | $0.862 | +596.06% | 14 | Aug 18, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $4.61 | +73.54% | 20 | Jun 25, 2026 | |
| SVRA Savara | Reiterated: Buy | $11 | $5.37 | +104.84% | 6 | Jun 3, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $11.02 | - | 3 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $10.73 | - | 19 | May 11, 2026 | |
| KROS Keros Therapeutics | Rated: Hold | n/a | $11.19 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $66.88 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.79 | - | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.39 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $96.47 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.11 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $494.63 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.54 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $98 | $78.09 | +25.50% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $17.11 | +133.78% | 7 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $42.02 | +47.55% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $9.65 | +335.23% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $7 | $2.09 | +234.93% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.83 | +391.80% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $20.11 | n/a | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $0.539 | n/a | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0232 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $10.02 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $105 | $16.94 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.1449 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $10.14 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $8.03 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $24.69 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $63.94 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $4 | $10.62 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $236.72 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.92 | n/a | 6 | Aug 25, 2022 |
Inhibikase Therapeutics
Oct 13, 2026
Initiated: Hold
Price Target: $1.5
Current: $1.85
Upside: -18.70%
Agenus
Sep 21, 2026
Initiated: Buy
Price Target: $40
Current: $8.19
Upside: +388.40%
Opus Genetics
Sep 9, 2026
Rated: Buy
Price Target: $13 → $16
Current: $5.18
Upside: +208.88%
EyePoint
Aug 18, 2026
Downgraded: Hold
Price Target: $65 → $5
Current: $3.85
Upside: +29.87%
Rani Therapeutics Holdings
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $0.862
Upside: +596.06%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $4.61
Upside: +73.54%
Savara
Jun 3, 2026
Reiterated: Buy
Price Target: $11
Current: $5.37
Upside: +104.84%
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.02
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.73
Upside: -
Keros Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.19
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $66.88
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.79
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.39
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $96.47
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $4.11
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $494.63
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $3.54
Upside: -
Apr 24, 2026
Reiterated: Buy
Price Target: $105 → $98
Current: $78.09
Upside: +25.50%
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $17.11
Upside: +133.78%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $42.02
Upside: +47.55%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $9.65
Upside: +335.23%
Nov 11, 2025
Reiterated: Buy
Price Target: $3 → $7
Current: $2.09
Upside: +234.93%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.83
Upside: +391.80%
Oct 9, 2025
Reiterated: Buy
Price Target: $37
Current: $20.11
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $0.539
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.0232
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $10.02
Upside: n/a
Aug 13, 2024
Reiterated: Hold
Price Target: $105
Current: $16.94
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.1449
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $10.14
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $8.03
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $24.69
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $63.94
Upside: n/a
Feb 22, 2024
Reiterated: Buy
Price Target: $7 → $4
Current: $10.62
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $236.72
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $1.92
Upside: n/a